<DOC>
	<DOC>NCT00202917</DOC>
	<brief_summary>The purpose of this study is to study the feasibility and Toxicity of allogeneic haploidentical hematopoietic cell transplantation with CD3/CD19 depleted stem cells and a dose reduced conditioning.</brief_summary>
	<brief_title>Haploidentical Transplantation With CD3/CD19 Depleted Grafts in Patients With Hematologic Malignancies</brief_title>
	<detailed_description>Transplantation of a CD3/CD19 depleted stem cell grafts after dose reduced conditioning for the treatment of treatment refractory or relapsed hematologic malignancies after preceding allogeneic or autologous hematopoietic cell transplantation.</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>Age &lt;60, &gt;18 years Karnofsky &gt;60% High risk hematologic malignancy or relapse after preceding auto/allo HCT in patients with: ALL AML PNH MDS (RAEBt/secondary AML) NHL ALL HD CML MM No HLAidentical MRD or URD if not preceding alloHCT Use haploidentical donor with KIRMismatch if choice &lt; 3 months after preceding HCT Active cerebral seizures &gt; 30% blasts in BM if ALL/AML/CMLBC Completely chemorefractory Preceding myocardial infarction Ejection fraction &lt;30 % echocardiography Creatinine clearance &lt;50 ml/min Respiratory insufficiency on supplemental O2 or DLCO &lt; 30% Allergy against murine antibodies HIV infection Pregnancy Unable for informed consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>haploidentical transplantation</keyword>
	<keyword>immunomagnetic cell sorting</keyword>
	<keyword>allogeneic hematopoietic cell transplantation</keyword>
	<keyword>dose reduced conditioning</keyword>
</DOC>